This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Endometriosis Patients Undergoing Quinagolide Treatment

This study has been completed.
Information provided by:
Instituto Valenciano de Infertilidad, IVI VALENCIA Identifier:
First received: February 20, 2008
Last updated: January 9, 2009
Last verified: January 2009
Dopamine agonists, such as quinagolide, are able to act on the VEGFR-2 blocking antibodies, diminishing Vascular Endothelial Growth Factor effect on angiogenesis in human endometriotic lesions.

Condition Intervention Phase
Hyperprolactinemia Endometriosis Procedure: ENDOMETRIAL BIOPSY Phase 4

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Health Services Research
Official Title: Effect of Treatment With Agonist Dopaminergics on Endometriosic Lesions.

Resource links provided by NLM:

Further study details as provided by Instituto Valenciano de Infertilidad, IVI VALENCIA:

Primary Outcome Measures:
  • observation of three month treatment with Quinagolida in endometriosis patients [ Time Frame: onset and three months after onset ]

Estimated Enrollment: 5
Study Start Date: February 2008
Study Completion Date: May 2008
Primary Completion Date: April 2008 (Final data collection date for primary outcome measure)
Intervention Details:
    Two routine laparoscopies in period of three months with endometrial biopsy comparative study performed.

Ages Eligible for Study:   18 Years to 37 Years   (Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Hyperprolactinemia
  • Unexplained infertility
  • Endometriosis
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00625950

Instituto Valenciano de Infertilidad
Valencia, Spain, 46015
Sponsors and Collaborators
Instituto Valenciano de Infertilidad, IVI VALENCIA
  More Information

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Prof. Dr. Antonio Pellicer, Instituto Valenciano de Infertilidad, Spain Identifier: NCT00625950     History of Changes
Other Study ID Numbers: VLC-AP-10208-208-1
Study First Received: February 20, 2008
Last Updated: January 9, 2009

Keywords provided by Instituto Valenciano de Infertilidad, IVI VALENCIA:
angiogenesis, VEGF

Additional relevant MeSH terms:
Genital Diseases, Female
Pituitary Diseases
Hypothalamic Diseases
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Endocrine System Diseases processed this record on September 20, 2017